logo

FDA Calendar

Share
Company Name Regeneron Pharmaceuticals
Drug Name Dupixent (sBLA)
Event Name FDA decision on Dupixent as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
Event Date 05/26/2020
Outcome Date 05/26/2020
Outcome FDA approved Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis on May 26, 2020
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar